Fate Of COVID-19 Convalescent Plasma Clinical Trials At Stake As US FDA Weighs EUA
Executive Summary
Clinical trials would have to move outside US if agency issues emergency use authorization for convalescent plasma, NYU prof says; experts disagree on whether the FDA should issue EUA.
You may also be interested in...
Email Trove From US FDA Shows Peter Marks As Champion For Plasma Authorization
The emergency use authorization for convalescent plasma in August 2020 on weak data from an expanded access program has largely been viewed as a politically charged decision by the Trump administration. But newly revealed emails from the run up to the decision indicate Center for Biologics Evaluation and Research Director Peter Marks backed the plan.
Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire
Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.
Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire
Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.